Business Context and Reporting Period
Rani Therapeutics Holdings, Inc. (RANI) is a clinical-stage biotherapeutics company developing the RaniPill, a drug-agnostic oral delivery platform designed to administer biologics and drugs orally as an alternative to injections. The company operates as a holding company with its principal asset being an interest in Rani Therapeutics, LLC. This Form 10-K covers the fiscal year ended December 31, 2025.
The company has no approved products and has not generated commercial product revenue. Its strategy focuses on advancing its pipeline of oral therapeutics (including RT-114 for obesity and RT-111 for inflammatory conditions) and entering into strategic partnerships to license its technology.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Contract Revenue | $1.6 million | $1.0 million |
| Total Operating Expenses | $40.0 million | $54.3 million |
| Net Loss | $(41.0) million | $(56.6) million |
| Net Loss Attributable to Rani Holdings | $(29.7) million | $(30.0) million |
| Cash, Cash Equivalents, and Marketable Securities | $49.7 million | $27.6 million |
| Net Cash Used in Operating Activities | $(18.7) million | $(35.5) million |
| Debt Obligations | $0 (Fully repaid) | $24.6 million (Outstanding) |
Note: The company reported a net loss of approximately $41.0 million for 2025. There were no commercial product sales; revenue was derived from collaboration and evaluation agreements.
Material Changes vs. Prior Period
- Revenue Growth: Contract revenue increased 58.9% to $1.6 million, driven primarily by a $1.5 million upfront payment from a new collaboration with Chugai Pharmaceutical Co., Ltd.
- Expense Reduction: Total operating expenses decreased 26.5% to $40.0 million. Research and Development (R&D) expenses fell 24.3% to $20.2 million, and General and Administrative (G&A) expenses fell 17.6% to $19.7 million, reflecting cost containment measures and the pause of certain programs.
- Debt Elimination: The company repaid all outstanding debt obligations in December 2025, including a remaining principal balance of $6.2 million, accrued interest, and fees. This resulted in a $0.6 million loss on extinguishment of debt.
- Liquidity Improvement: Cash and marketable securities increased significantly from $27.6 million to $49.7 million, bolstered by a $60.3 million private placement in October 2025 and other financing activities.
- Impairment: Unlike 2024, which included a $3.7 million impairment loss on construction-in-progress, no impairment loss was recorded in 2025.
Guidance, Outlook, and Risks
Outlook and Pipeline:
- The company initiated a Phase 1 clinical trial for RT-114 (GLP-1/GLP-2 dual agonist for obesity) in December 2025.
- Development of RT-102 and RT-110 (endocrinology programs) was discontinued in 2026 to prioritize obesity, immunology, and partner programs.
- Management believes current cash resources are sufficient to fund operations for at least the next twelve months.
Material Risks and Contingencies:
- Internal Controls: The company identified a material weakness in internal control over financial reporting related to the accounting for significant and complex transactions. Disclosure controls and procedures were deemed ineffective as of December 31, 2025.
- Going Concern: While liquidity improved, the company has incurred recurring losses and expects to continue doing so. Future funding will be required to complete clinical development and commercialization.
- Regulatory Uncertainty: As an early-stage company with no approved products, the company faces significant risks regarding the ability to obtain regulatory approval for its novel combination products (biologic-device).
- Collaboration Dependence: Future revenue is heavily dependent on the success of collaborations with partners like Chugai and ProGen, including the achievement of milestone payments.
Key Facts for Investor Verification
- Material Weakness Remediation: Verify the specific steps management is taking to remediate the identified material weakness in internal controls and the timeline for effectiveness.
- Chugai Collaboration Terms: Confirm the recognition timeline for the $10.0 million upfront payment and the probability of achieving the $18.0 million in technology transfer milestones and $57.0 million in development milestones.
- Debt Repayment Details: Review the specific terms of the debt extinguishment and the impact of the $0.6 million loss on the company's financial position.
- Capital Requirements: Assess the sufficiency of the $49.7 million cash balance against the projected burn rate for advancing RT-114 and other pipeline candidates through Phase 1 and beyond.
- Stock Dilution: Note the significant increase in outstanding shares and warrants following the October 2025 private placement and subsequent warrant exercises.